Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Institutional & Insider Ownership
27.9% of Dyadic International shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Mirum Pharmaceuticals and Dyadic International”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $521.31 million | 10.01 | -$23.36 million | ($14.55) | -5.53 |
| Dyadic International | $3.09 million | 5.17 | -$7.36 million | ($0.23) | -1.73 |
Dyadic International has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Mirum Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Mirum Pharmaceuticals and Dyadic International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
| Dyadic International | 1 | 0 | 0 | 0 | 1.00 |
Mirum Pharmaceuticals presently has a consensus target price of $148.19, indicating a potential upside of 84.34%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Mirum Pharmaceuticals is more favorable than Dyadic International.
Profitability
This table compares Mirum Pharmaceuticals and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -139.18% | -36.28% | -8.54% |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
Summary
Mirum Pharmaceuticals beats Dyadic International on 9 of the 14 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
